Needs and challenges:
Click on the unit operation below to find productivity and throughput solutions you can implement today.
![]() |
KrosFlo® TFDF™ Systems |
---|
Closed, single-use, automated, alternative to centrifugation and primary depth filtration Ideal for Lentivirus processes: Improved yields low shear, low hold-up volumes Scalable from 1 to 2000L |
![]() |
SoloVPE™ Device |
---|
Rapid and accurate absorbance measurements; Avoid labor-intensive, precision-impacting sample dilution Automated plasmid/viral vector concentration measurement with increased assay variability and repeatability |
Gene Therapy has immense potential to transform the lives of patients with genetic diseases. As demand for plasmids and viral vectors outpace capacity, a greater than 10-fold and potentially close to 100-fold increase in manufacturing efficiency for the gene therapy reagents is likely required to meet a demand curve that is increasing exponentially. Repligen solutions aim to meet the needs for optimized processes, higher yields, and improved process quality - setting new standards for modern scalable processes from gene to therapy.
Repligen Field Application Specialists (FAS) with expertise in Gene Therapy provide support from consultation to implementation globally.
Lentiviral vector manufacturing process enchancement utilizing TFDF™ technology
by Thomas Williams, Oliver Goodyear, Lee Davies, Carol Knevelman, Michael Bransby, Kyriacos Mitrophanous and James Miskin
Cell and Gene Therapy Insights, April 2020
AAV Studies Deploying a Closed, Irradiated, Single-use Flat Sheet TFF Device
by David Bianchi, Carl Breuning, Michael LaBreck, Shelly Parra, Mary Jo Wojtusik, Repligen Corporation
Alex Meola, Michael Mercaldi, Thomas Thiers, Homology, Medicines Inc.
Repligen Corporation
Homology, Medicines Inc.
July 2020